A phase II trial of pembrolizumab and lenvatinib in recurrent or persistent clear cell ovarian carcinoma (NCT05296512): stage 1 results

被引：0
作者：
Lee, Elizabeth [1 ]
Zhou, Yinglu [2 ]
Hendrickson, Andrea Wahner [3 ]
Fleming, Gini [4 ]
Konstantinopoulos, Panagiotis [1 ]
Krasner, Carolyn [1 ]
Stover, Elizabeth [1 ]
Horowitz, Neil [5 ]
Porter, Rebecca [1 ]
Wright, Alexi [1 ]
Matulonis, Ursula [1 ]
Xiong, Niya [2 ]
Sawyer, Hannah [1 ]
Tayob, Nabihah [2 ]
Liu, Joyce [1 ]
机构：
[1] Dana Farber Canc Inst, Med Oncol, Boston, MA USA
[2] Dana Farber Canc Inst, Data Sci, Boston, MA 02115 USA
[3] Mayo Clin, Comprehens Canc Ctr, Rochester, MN 55906 USA
[4] Univ Chicago, Med Oncol, Chicago, IL USA
[5] Brigham & Womens Hosp, Div Gynecol Oncol, Dana Farber Canc Inst, Boston, MA 02115 USA
来源：
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER | 2024年 / 34卷 / SUPPL_3期
关键词：
D O I：
10.1136/ijgc-2024-IGCS.12
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LB009/#156
引用
收藏
页码：A11 / A12
页数：2
相关论文
共 50 条
  • [41] Phase II Trial of Capecitabine and Cisplatin in Advanced, Persistent, or Recurrent Carcinoma of the Cervix
    Errihani, Hassan
    M'rabti, Hind
    Ismaili, Nabil
    Inrhaoun, Hanane
    Elghissassi, Ibrahim
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2011, 21 (02) : 373 - 377
  • [42] A phase II study of gemcitabine, cisplatin, and bevacizumab for first recurrent and refractory ovarian clear-cell carcinoma (KCOG-G1601 trial)
    Ito, K.
    Nakagawa, M.
    Hori, K.
    Tashima, L.
    Goto, M.
    Yanagida, S.
    Suzuki, J.
    Kaya, R.
    Kawabata, A.
    Park, J.
    Nasu, H.
    Nishio, S.
    Kondo, E.
    Kaneda, M.
    Tsubamoto, H.
    Arakawa, A.
    Nagasawa, T.
    Yamada, K.
    ANNALS OF ONCOLOGY, 2020, 31 : S627 - S627
  • [43] Pembrolizumab in Patients with Refractory Cutaneous Squamous Cell Carcinoma: A Phase II Trial
    Renata Ferrarotto
    Luana G. Sousa
    Yun Qing
    Diana Kaya
    Bettzy Stephen
    Dipti Jain
    Diana Bell
    Shubham Pant
    Apostolia M. Tsimberidou
    Filip Janku
    George Blumenschein
    Bonnie S. Glisson
    Jordi Rodon Ahnert
    Sarina A. Piha-Paul
    J. Jack Lee
    Michael K. Wong
    Charles Lu
    Funda Meric-Bernstam
    Aung Naing
    Advances in Therapy, 2021, 38 : 4581 - 4591
  • [44] Surufatinib combined with toripalimab for the treatment of recurrent ovarian clear cell carcinoma: a prospective single center, single-arm phase II clinical trial
    Ye, Shuang
    Fu, Yi
    Liu, Shuai
    Wang, Jun
    Zhou, Lin
    Jiang, Wei
    Pei, Xuan
    Shen, Wenbin
    Sun, Min
    Shan, Boer
    Yang, Huijuan
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2024, 34 (SUPPL_3) : A262 - A263
  • [45] NeoPeLe: A phase II trial of neoadjuvant (NAT) pembrolizumab (Pembro) combined with lenvatinib (Lenva) in resectable stage III melanoma
    Long, G. V.
    Spillane, A. J.
    Pennington, T. E.
    Shannon, K. F.
    Stretch, J.
    Gonzalez, M.
    Saw, R. P. M.
    Lo, S. N.
    Scolyer, R. A.
    Menzies, A. M.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S906 - S907
  • [46] Setanaxib plus pembrolizumab for the treatment of recurrent or metastatic squamous cell carcinoma of the head & neck: Results of a randomized, double-blind phase II trial
    Fayette, J.
    Thomas, G.
    Daste, A.
    Rotarski, M.
    Castelo, B.
    Rullan, A.
    Levine, A.
    Philipson, R. S.
    Harrington, K. J.
    ANNALS OF ONCOLOGY, 2024, 35 : S615 - S616
  • [47] A phase II evaluation of sunitinib in the treatment of persistent or recurrent clear cell ovarian carcinoma: An NRG Oncology/Gynecologic Oncology Group Study (GOG-254)
    Chan, John K.
    Brady, William
    Monk, Bradley J.
    Brown, Jubilee
    Shahin, Mark S.
    Rose, Peter G.
    Kim, Jae-Hoon
    Secord, Angeles Alvarez
    Walker, Joan L.
    Gershenson, David M.
    GYNECOLOGIC ONCOLOGY, 2018, 150 (02) : 247 - 252
  • [48] Salvage Chemotherapy for Patients With Recurrent or Persistent Ovarian Clear Cell Carcinoma A Retrospective Study of 164 Cases
    Bai, Huimin
    Sha, Guihua
    Cao, Dongyan
    Yang, Jiaxin
    Chen, Jie
    Wang, Yue
    Lang, Jinghe
    Shen, Keng
    Zhang, Zhenyu
    MEDICINE, 2015, 94 (27) : e1121
  • [49] Pembrolizumab in Patients with Refractory Cutaneous Squamous Cell Carcinoma: A Phase II Trial
    Ferrarotto, Renata
    Sousa, Luana G.
    Qing, Yun
    Kaya, Diana
    Stephen, Bettzy
    Jain, Dipti
    Bell, Diana
    Pant, Shubham
    Tsimberidou, Apostolia M.
    Janku, Filip
    Blumenschein, George
    Glisson, Bonnie S.
    Ahnert, Jordi Rodon
    Piha-Paul, Sarina A.
    Lee, J. Jack
    Wong, Michael K.
    Lu, Charles
    Meric-Bernstam, Funda
    Naing, Aung
    ADVANCES IN THERAPY, 2021, 38 (08) : 4581 - 4591
  • [50] A phase Ib/II trial of lenvatinib plus pembrolizumab in non-small cell lung cancer.
    Brose, Marcia S.
    Vogelzang, Nicholas J.
    DiSimone, Christopher
    Jain, Sharad K.
    Richards, Donald A.
    Encarnacion, Carlos A.
    Rasco, Drew W.
    Shumaker, Robert Charles
    Dutcus, Corina E.
    Stepan, Daniel E.
    Guo, Matthew
    Schmidt, Emmett V.
    Taylor, Matthew H.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (08)
12345